English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Tyrosine kinase inhibitors ( TKI ) are used for primary therapy in patients with newly diagnosed  CML . However, a reliable method for optimal selection of a  TKI  from the viewpoint of drug sensitivity of  CML  cells has not been established. We have developed a  FRET ‐based drug sensitivity test in which a CrkL‐derived fluorescent biosensor efficiently quantifies the kinase activity of  BCR ‐ ABL  of living cells and sensitively evaluates the inhibitory activity of a  TKI  against  BCR ‐ ABL . Here, we validated the utility of the  FRET ‐based drug sensitivity test carried out at diagnosis for predicting the molecular efficacy. Sixty‐two patients with newly diagnosed chronic phase  CML  were enrolled in this study and treated with dasatinib. Bone marrow cells at diagnosis were subjected to  FRET  analysis. The Δ FRET  value was calculated by subtraction of  FRET  efficiency in the presence of dasatinib from that in the absence of dasatinib. Treatment response was evaluated every 3 months by the   BCR ‐ ABL 1  International Scale. Based on the Δ FRET  value and molecular response, a threshold of the Δ FRET  value in the top 10% of  FRET  efficiency was set to 0.31. Patients with Δ FRET  value ≥0.31 had significantly superior molecular responses ( MMR  at 6 and 9 months and both  MR 4 and  MR 4.5 at 6, 9, and 12 months) compared with the responses in patients with Δ FRET  value &lt;0.31. These results suggest that the  FRET ‐based drug sensitivity test at diagnosis can predict early and deep molecular responses. This study is registered with  UMIN  Clinical Trials Registry ( UMIN 6358).

cancer science

Pretreatment evaluation of fluorescence resonance energy transfer‐based drug sensitivity test for patients with chronic myelogenous leukemia treated with dasatinib